Up Close with Epcoritamab
Last Updated: July 24, 2026
Discover more about epcoritamab-bysp (EPKINLY®).
Related Resources:
PQI in Action
PQI in Action: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Last Updated: 10/09/2025
PQI
PQI: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Last Updated: 05/05/2026
Perspectives
OncolyticsToday: The Bispecific Antibody Revolution
Author: KELLY BRUNK
Last Updated: 04/01/2024
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Up Close with Linvoseltamab
Last Updated: 06/29/2026
Overview of BTCEs: Comparison of Bispecific T-Cell Engagers (BTCEs)
Last Updated: 04/23/2026
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/01/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/01/2025
Patient Education Sheet
PQI in Action
Patient Education Sheet
Treatment Support Kit
Bacillus Calmette-Guérin
Last Updated: 08/06/2026
PQI in Action: Inavolisib (Itovebi) Patient Management
Last Updated: 08/01/2026
Mycophenolate
Last Updated: 07/27/2026
Treatment Support Kit: Avutometinib and Defactinib
Last Updated: 08/06/2025